...
首页> 外文期刊>Journal of Surgical Oncology >Repeat hepatectomy for colorectal liver metastases: A worthwhile operation?
【24h】

Repeat hepatectomy for colorectal liver metastases: A worthwhile operation?

机译:重复肝切除术治疗大肠肝转移:值得进行手术吗?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND OBJECTIVES: After curative resection of hepatic colorectal metastases, 10-20% of patients experience a resectable hepatic recurrence. We wanted to assess the expected risk-to-benefit ratio in comparison to first hepatectomy and to determine the prognostic factors associated with survival. METHODS: Twenty-nine patients from a group of 152 patients resected for colorectal liver metastases underwent 32 repeat hepatectomies. RESULTS: In-hospital mortality was 3.5% (1/29 patients); the morbidity after repeat hepatectomy was lower than that after first hepatic resection. Combined extrahepatic surgery was performed on 34.5% of repeat hepatectomies vs. 6.9% of first hepatectomies (P = 0.01). Overall actuarial 3-year survival was 35.1%: four patients have survived more than 3 years and one survived for more than 5 years. The number of hepatic metastases and the carcinoembryonic antigen (CEA) serum levels were significant prognostic factors on univariate analysis. The synchronous resection of hepatic and extrahepatic disease was not associated with a lower survival rate when compared with that of patients without extrahepatic localization: three patients of the former group are alive and disease-free at more than 2 years. CONCLUSIONS: Repeat hepatic resection can provide long-term survival rates similar to those of first liver resection, with comparable mortality and morbidity. The presence of resectable extrahepatic disease must not be an absolute contraindication to synchronous hepatectomy because long-term survival is possible.
机译:背景和目的:治愈性切除肝大肠转移瘤后,有10-20%的患者会发生可切除的肝癌复发。我们想评估与首次肝切除术相比的预期风险收益比,并确定与生存相关的预后因素。方法:从152例因结直肠肝转移而切除的患者中,对29例患者进行了32次重复肝切除术。结果:住院死亡率为3.5%(1/29例患者);重复肝切除术后的发病率低于第一次肝切除术后。联合肝外手术是对34.5%的重复肝切除术与6.9%的第一肝切除术进行比较(P = 0.01)。总体精算3年生存率为35.1%:4例患者生存3年以上,1例生存5年以上。单因素分析显示,肝转移的数目和癌胚抗原(CEA)血清水平是重要的预后因素。与没有肝外定位的患者相比,同步切除肝和肝外疾病的生存率并不低:前一组中有3例患者活着且无病,病程超过2年。结论:重复肝切除术可提供与首次肝切除术相似的长期生存率,且死亡率和发病率相当。可切除的肝外疾病的存在绝不能是同步肝切除术的绝对禁忌症,因为它可以长期生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号